TVRD
Tvardi Therapeutics, Inc.Key Statistics
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-26.65M |
| Operating Margin | 0.00% |
| Return on Equity | -237.80% |
| Return on Assets | -49.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.23 |
| Price-to-Book | 1.35 |
| Price-to-Sales (TTM) | 559.61 |
| EV/Revenue | 539.62 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.38M |
| Float | $6.46M |
| % Insiders | 34.66% |
| % Institutions | 30.17% |
Historical Volatility
Volatility is currently contracting